Evaluation of XYA02 in Patients With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Jul 15, 2029 → Sep 15, 2029
See other at-risk trials from XYone Therapeutics, Inc

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Primary completion pushed from Jul 15, 2029 to Sep 15, 2029
    • Study completion pushed from Jul 15, 2030 to Sep 15, 2030
    • Start date changed from estimate of Jul 15, 2026 to Sep 17, 2026
    • Eligibility criteria expanded, about 28 words
    • Site details revised at 5 of 5 sites
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
XYone Therapeutics, Inc
1 trial monitored
See 1 trial at risk
Lung Cancer
4,798 trials monitored
See 270 trials at risk
Colorectal Cancer
3,405 trials monitored
See 162 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
3,085 trials monitored
See 178 trials at risk
and 3 more diseases
This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.
Trial Details
NCT Number NCT07670312
Lead Sponsor XYone Therapeutics, Inc
Collaborators: Novotech (Australia) Pty Limited
Conditions
(from sponsor)		 MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, GEJ Adenocarcinoma, Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer
Related terms Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
Enrollment 190 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov